Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Diamedica Therapeutics ( (DMAC) ) just unveiled an update.
DiaMedica Therapeutics announced updates to its ReMEDy2 trial for acute ischemic stroke, including expanding the patient pool and increasing interim analysis size, aimed at enhancing trial success and reducing costs. The company also reported regulatory approval for a Phase 2 trial of DM199 for preeclampsia in South Africa. Financially, DiaMedica has $50.2 million in cash and investments, with increased R&D expenses reflecting ongoing trial expansions.
Learn more about DMAC stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue